title: A critical question for cancer therapy: what new targets exist?
abstract: Designing molecular targeted therapy with high specificity based on novel tumor biomarkers is a high priority in lung cancer research. Several molecular aberrations have been already identified in non-small cell lung cancer (NSCLC), with subsequent development of drugs targeted to these aberrations. A more recent actionable target is MET, a multifaceted receptor tyrosine kinase which frequently interacts with other key oncogenic tyrosine kinases including epidermal growth factor receptor (EGFR) and ERBB3 leading to resistance to anti-EGFR therapies. However a phase III trial enrolling only patients with MET-positive tumors was stopped in early March due to futility since there was no evidence that the addition of onartuzumab to erlotinib has any positive effect. From the results of the MET lung phase III trial, we provide new pieces of information that can contribute to further preclinical validation and also be part of the armamentarium for clinical translational research.
authors: 1 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 2 Molecular Oncology Research (MORe) Foundation, Sabino Arana 5-19, Barcelona, Spain ; 3 Instituto Oncológico Dr Rosell, Barcelona, Spain ; 4 Pangaea Biotech S.L, Sabino Arana 5-19, Barcelona, Spain ; 5 Institut Quìmic de Sarrià, Via Augusta 390, Barcelona, Spain ; 6 Fundació Institut de Investigació Germans Trias i Pujol, Badalona, Spain ; 7 Instituto Oncológico Nacional, Calle Gorgas, Ancon, Panamá
authors: Rafael
authors: R
authors: Rosell
authors: 1 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 2 Molecular Oncology Research (MORe) Foundation, Sabino Arana 5-19, Barcelona, Spain ; 3 Instituto Oncológico Dr Rosell, Barcelona, Spain ; 4 Pangaea Biotech S.L, Sabino Arana 5-19, Barcelona, Spain ; 5 Institut Quìmic de Sarrià, Via Augusta 390, Barcelona, Spain ; 6 Fundació Institut de Investigació Germans Trias i Pujol, Badalona, Spain ; 7 Instituto Oncológico Nacional, Calle Gorgas, Ancon, Panamá
authors: Niki
authors: N
authors: Karachaliou
authors: 1 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 2 Molecular Oncology Research (MORe) Foundation, Sabino Arana 5-19, Barcelona, Spain ; 3 Instituto Oncológico Dr Rosell, Barcelona, Spain ; 4 Pangaea Biotech S.L, Sabino Arana 5-19, Barcelona, Spain ; 5 Institut Quìmic de Sarrià, Via Augusta 390, Barcelona, Spain ; 6 Fundació Institut de Investigació Germans Trias i Pujol, Badalona, Spain ; 7 Instituto Oncológico Nacional, Calle Gorgas, Ancon, Panamá
authors: Jordi
authors: J
authors: Codony
authors: 1 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 2 Molecular Oncology Research (MORe) Foundation, Sabino Arana 5-19, Barcelona, Spain ; 3 Instituto Oncológico Dr Rosell, Barcelona, Spain ; 4 Pangaea Biotech S.L, Sabino Arana 5-19, Barcelona, Spain ; 5 Institut Quìmic de Sarrià, Via Augusta 390, Barcelona, Spain ; 6 Fundació Institut de Investigació Germans Trias i Pujol, Badalona, Spain ; 7 Instituto Oncológico Nacional, Calle Gorgas, Ancon, Panamá
authors: Cristina
authors: C
authors: Teixido
authors: 1 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 2 Molecular Oncology Research (MORe) Foundation, Sabino Arana 5-19, Barcelona, Spain ; 3 Instituto Oncológico Dr Rosell, Barcelona, Spain ; 4 Pangaea Biotech S.L, Sabino Arana 5-19, Barcelona, Spain ; 5 Institut Quìmic de Sarrià, Via Augusta 390, Barcelona, Spain ; 6 Fundació Institut de Investigació Germans Trias i Pujol, Badalona, Spain ; 7 Instituto Oncológico Nacional, Calle Gorgas, Ancon, Panamá
authors: Silvia
authors: S
authors: Garcia-Roman
authors: 1 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 2 Molecular Oncology Research (MORe) Foundation, Sabino Arana 5-19, Barcelona, Spain ; 3 Instituto Oncológico Dr Rosell, Barcelona, Spain ; 4 Pangaea Biotech S.L, Sabino Arana 5-19, Barcelona, Spain ; 5 Institut Quìmic de Sarrià, Via Augusta 390, Barcelona, Spain ; 6 Fundació Institut de Investigació Germans Trias i Pujol, Badalona, Spain ; 7 Instituto Oncológico Nacional, Calle Gorgas, Ancon, Panamá
authors: Daniela
authors: D
authors: Morales
authors: 1 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 2 Molecular Oncology Research (MORe) Foundation, Sabino Arana 5-19, Barcelona, Spain ; 3 Instituto Oncológico Dr Rosell, Barcelona, Spain ; 4 Pangaea Biotech S.L, Sabino Arana 5-19, Barcelona, Spain ; 5 Institut Quìmic de Sarrià, Via Augusta 390, Barcelona, Spain ; 6 Fundació Institut de Investigació Germans Trias i Pujol, Badalona, Spain ; 7 Instituto Oncológico Nacional, Calle Gorgas, Ancon, Panamá
authors: María González
authors: MG
authors: Cao
authors: 1 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 2 Molecular Oncology Research (MORe) Foundation, Sabino Arana 5-19, Barcelona, Spain ; 3 Instituto Oncológico Dr Rosell, Barcelona, Spain ; 4 Pangaea Biotech S.L, Sabino Arana 5-19, Barcelona, Spain ; 5 Institut Quìmic de Sarrià, Via Augusta 390, Barcelona, Spain ; 6 Fundació Institut de Investigació Germans Trias i Pujol, Badalona, Spain ; 7 Instituto Oncológico Nacional, Calle Gorgas, Ancon, Panamá
authors: Santiago
authors: S
authors: Viteri
authors: 1 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 2 Molecular Oncology Research (MORe) Foundation, Sabino Arana 5-19, Barcelona, Spain ; 3 Instituto Oncológico Dr Rosell, Barcelona, Spain ; 4 Pangaea Biotech S.L, Sabino Arana 5-19, Barcelona, Spain ; 5 Institut Quìmic de Sarrià, Via Augusta 390, Barcelona, Spain ; 6 Fundació Institut de Investigació Germans Trias i Pujol, Badalona, Spain ; 7 Instituto Oncológico Nacional, Calle Gorgas, Ancon, Panamá
authors: Ignacio
authors: I
authors: Veliz
authors: 1 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 2 Molecular Oncology Research (MORe) Foundation, Sabino Arana 5-19, Barcelona, Spain ; 3 Instituto Oncológico Dr Rosell, Barcelona, Spain ; 4 Pangaea Biotech S.L, Sabino Arana 5-19, Barcelona, Spain ; 5 Institut Quìmic de Sarrià, Via Augusta 390, Barcelona, Spain ; 6 Fundació Institut de Investigació Germans Trias i Pujol, Badalona, Spain ; 7 Instituto Oncológico Nacional, Calle Gorgas, Ancon, Panamá
authors: Yong
authors: Y
authors: Loo
authors: 1 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 2 Molecular Oncology Research (MORe) Foundation, Sabino Arana 5-19, Barcelona, Spain ; 3 Instituto Oncológico Dr Rosell, Barcelona, Spain ; 4 Pangaea Biotech S.L, Sabino Arana 5-19, Barcelona, Spain ; 5 Institut Quìmic de Sarrià, Via Augusta 390, Barcelona, Spain ; 6 Fundació Institut de Investigació Germans Trias i Pujol, Badalona, Spain ; 7 Instituto Oncológico Nacional, Calle Gorgas, Ancon, Panamá
authors: Omar
authors: O
authors: Castillo
keywords: Epidermal growth factor receptor (EGFR); MET; non-small cell lung cancer (NSCLC); targeted therapy